IL138681A0 - Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b - Google Patents

Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Info

Publication number
IL138681A0
IL138681A0 IL13868199A IL13868199A IL138681A0 IL 138681 A0 IL138681 A0 IL 138681A0 IL 13868199 A IL13868199 A IL 13868199A IL 13868199 A IL13868199 A IL 13868199A IL 138681 A0 IL138681 A0 IL 138681A0
Authority
IL
Israel
Prior art keywords
attenuation
respiratory syncytial
virus
human respiratory
subgroup
Prior art date
Application number
IL13868199A
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL138681A0 publication Critical patent/IL138681A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL13868199A 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b IL138681A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7946698P 1998-03-26 1998-03-26
PCT/US1999/006225 WO1999049017A2 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Publications (1)

Publication Number Publication Date
IL138681A0 true IL138681A0 (en) 2001-10-31

Family

ID=22150746

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13868199A IL138681A0 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Country Status (9)

Country Link
EP (1) EP1064358A2 (en)
JP (1) JP2002507408A (en)
KR (1) KR20010080863A (en)
CN (2) CN1177927C (en)
AU (1) AU767193B2 (en)
BR (1) BR9909076A (en)
CA (1) CA2323927A1 (en)
IL (1) IL138681A0 (en)
WO (1) WO1999049017A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE343589T1 (en) * 2000-06-23 2006-11-15 Wyeth Corp MODOFIED MORBILLIVIRUS V PROTEINS
ES2330309T3 (en) * 2002-06-20 2009-12-09 Institut Pasteur INFECTIOUS cDNA OF AN APPROVED VACCINE VIRUS strain of SARAMPION. USE FOR IMMUNOGENIC COMPOSITIONS.
WO2004087062A2 (en) 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
WO2008065752A1 (en) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Immunotherapeutic agent containing dirna as active ingredient
WO2010053883A1 (en) 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
JP6453063B2 (en) * 2014-12-02 2019-01-16 国立大学法人北海道大学 Adjuvant composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045581B2 (en) * 1991-10-14 2000-05-29 社団法人北里研究所 Measles vaccine virus strain identification method
TW275632B (en) * 1992-04-21 1996-05-11 American Cyanamid Co
EP0932684A2 (en) * 1996-09-27 1999-08-04 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Also Published As

Publication number Publication date
AU767193B2 (en) 2003-11-06
EP1064358A2 (en) 2001-01-03
CA2323927A1 (en) 1999-09-30
AU3109599A (en) 1999-10-18
KR20010080863A (en) 2001-08-25
CN1600852A (en) 2005-03-30
JP2002507408A (en) 2002-03-12
CN1177927C (en) 2004-12-01
BR9909076A (en) 2000-12-05
WO1999049017A3 (en) 1999-12-16
WO1999049017A2 (en) 1999-09-30
CN1294628A (en) 2001-05-09

Similar Documents

Publication Publication Date Title
EG24026A (en) Respiratory syncytial virus replication inhibitors
IL147327A0 (en) Respiratory syncytial virus replication inhibitors
HK1045998B (en) Respiratory syncytial virus replication inhibitors
EP1112091A4 (en) Rapid cryobaric sterilization and vaccine preparation
HK1042084B (en) Substituted benzimidazoles and their preparation and use
AP2001002366A0 (en) Systems and methods for aerosolizing pharmacetical formulations
IL139279A0 (en) Disposable pant-type diaper having improved protection against red marking and method for making the same
IL141562A0 (en) Particulate compositions for pulmonary delivery and methods for the preparation thereof
IL138609A0 (en) Antipicornaviral compounds, their preparation and use
HUP0102585A2 (en) Thienylazolylalcoxyethanamin derivatives preparation the same and their use as medicaments
EP0975363A4 (en) Attenuated respiratory syncytial virus
IL138681A0 (en) Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
ATE276234T1 (en) UREA DERIVATIVES FOR PAIN FIGHTING
AU2000277264A1 (en) Heat-moisture exchanger and nebulization device
AU6200399A (en) Avian pneumovirus vaccine and diagnostic agent
HUP0102409A3 (en) Pyrimidin-aminomethhyl-pyridine derivatives, their preparation and their use in the control of helicobacter bacteria
EP0917592A4 (en) Attenuated respiratory syncytial virus
AU9654601A (en) Method and composition for the treatment of blackwater collection systems
HUP0203771A3 (en) Disinfectant agent concentrate and its use
EP1096889A4 (en) Clean breath wand system
GB9927353D0 (en) Virus preparation and use
IL137076A0 (en) Bibapctitide-based pharmaceutical compositions for imaging and treating thrombi
LT98110A (en) Polytetra-ammonium salt, method for preparation and use thereof
HK1006915A2 (en) Vertebras orthopaedic net-support
SI1073672T1 (en) Antipicornaviral compounds, their preparation and use